Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...

The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices ...

The US will slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted ...

Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed ...

Novo Nordisk's diabetes medication, Ozempic, is one of 15 drugs set to enter Medicare price negotiations for the year 2027, ...

The late-stage trial of semaglutide, which it markets as Wegovy to treat obesity, showed that those who took a dose of 7.2 milligrams lost an average of 20.7% of their weight over 72 weeks. A third of ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its ...